Patients with a pathologically proven diagnosis of malignant melanoma were entered into a phase II trial of bisantrene. Eligibility criteria included: measurable, metastatic disease; performance status 0-2 SWOG; and adriamycin total cumulative dose of < 400 mg/m 2. The initial bisantrene dosing sche
A phase II study of bisantrene in malignant lymphomas
โ Scribed by Thomas P. Miller; John D. Cowan; Barbara A. Neilan; Stephen E. Jones
- Publisher
- Springer
- Year
- 1986
- Tongue
- English
- Weight
- 291 KB
- Volume
- 16
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without s
A phase I/II study of bisantrene using a 3-week schedule was undertaken in 171 children with refractory leukemias and solid tumors. The doses ranged from 190 to 430 mg/m2. The maximum tolerated dose for children with solid tumors and acute leukemias was 280 mg/m2 and 360 mg/m2 every 3 weeks, respect